Madrigal Pharmaceuticals, Inc.

Yeah, interestingly, that kind of mirrors something we've seen in another area of my coverage, which is liver disease.

Madrigal Therapeutics was the first company to get a drug approved for MASH, metabolic associated steatotic dysfunction.

I garbled that, but that's basically

what it

No use, broadcast, or recording of this presentation or any part thereof is permitted without the written authorization of Medscape.

The following presentation is part of a certified educational activity provided by Medscape Education and supported by an independent educational grant from Madrigal Pharmaceuticals

Welcome to Medscape's in-depth CME TV docuseries, Managing MASH in the Modern Era.

I'm your host, Taryn Winter-Brill.

Food waste is considered to be the largest contributor to U.S. landfills.

Madrigal Pharmaceuticals opened the doors to its new headquarters in Conshohocken today.

The company is the first to develop a therapy for the serious liver disease known as MASH.

Madrigal has quadrupled in size over the last three years, prompting the need to expand.